What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neuroblastoma
- Main trialPhase 1
- “The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.”In the company’s words, NCT04106219 on ClinicalTrials.gov
- Other names
- AK-01 · Erbumine
Other drugs for Neuroblastoma
- EB-DTNB-NKBeijing Biotech · Phase 1/2
- APG-115Ascentage Pharma Group Inc. · Phase 1/2
- LisaftoclaxAscentage Pharma Group Inc. · Phase 1/2
- EntrectinibRoche · Phase 1/2
- Zilovertamab vedotinMerck & Co. · Phase 1/2
- Allogenic NK cellsMarzieh Ebrahimi · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 13 Apr 2022 | A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | |
| Phase 1/2Completed | 20 Apr 2020 | A Study of AK-01 (LY3295668) in Solid Tumors | |
| Phase 1Completed | 2 Jun 2020 | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026